Trial to Evaluate the Effect of Eslicarbazepine Acetate on Cardiac Repolarization

A Study of a Drug to be Used in Addition With Another Drug to Treat Adults With Uncontrolled Partial-onset Seizures

NCT03116828 ·Status: COMPLETED ·Phase: PHASE4

Eslicarbazepine Acetate (BIA 2-093) as Monotherapy in Patients With Newly Diagnosed Partial-onset Seizures

NCT02484001 ·Status: COMPLETED ·Phase: PHASE3

Comparison of the Cognitive and Behavioral Effects of Eslicarbazepine Acetate and Carbamazepine in Healthy Adults

NCT02912364 ·Status: COMPLETED ·Phase: PHASE4

Food Effect and Dosage Form Proportionality Study of Eslicarbazepine Acetate

NCT02288312 ·Status: COMPLETED ·Phase: PHASE1

Efficacy and Safety of Eslicarbazepine Acetate as Adjunctive Therapy for Refractory Partial Epilepsy

NCT00957372 ·Status: COMPLETED ·Phase: PHASE3

Effect of Eslicarbazepine Acetate on the Pharmacokinetics of Gliclazide in Healthy Volunteers

NCT02777671 ·Status: COMPLETED ·Phase: PHASE1

Open-label Drug Interaction Study Between Eslicarbazepine Acetate and Phenytoin.

NCT02283827 ·Status: COMPLETED ·Phase: PHASE1

GSK Drug Single Dose Escalation And Their Effect On Resting Motor Threshold In Healthy Volunteers

NCT00488566 ·Status: COMPLETED ·Phase: PHASE1

Study to Evaluate Pharmacokinetics and Tolerability of Multiple Doses of Eslicarbazepine Acetate and Oxcarbazepine

NCT00900237 ·Status: COMPLETED ·Phase: PHASE1

A Open-label, Drug Interaction Study Between Eslicarbazepine Acetate and Topiramate

NCT02283814 ·Status: COMPLETED ·Phase: PHASE1

A Double-blind, Randomised, Placebo-controlled, Rising Multiple Dose Study to Investigate the Safety, Tolerability, Steady State Pharmacokinetic Profile and CNS Effects of BIA 2-093

NCT02171234 ·Status: COMPLETED ·Phase: PHASE1

Safety, Tolerability, and Pharmacokinetics (PK) of Single and Multiple Ascending Oral Doses of iQ-007

NCT06899230 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1

A Single Centre, Phase I, Double-blind, Randomised, Placebo-controlled Study to Investigate the Safety, Tolerability, Pharmacokinetic Profile and Effects on EEG of Single Rising Oral Doses of BIA 2-093

NCT02171195 ·Status: COMPLETED ·Phase: PHASE1

Safety and Efficacy of Eslicarbazepine Acetate Monotherapy in Subjects With Partial Epilepsy Not Well Controlled by Current Antiepileptic Drugs

NCT00866775 ·Status: COMPLETED ·Phase: PHASE3

ZEDEBAC: Zebinix Effects in Dependency of Baseline Conditions

NCT03082222 ·Status: COMPLETED

Anti-epileptogenic Effects of Eslicarbazepine Acetate

NCT06597084 ·Status: COMPLETED ·Phase: PHASE2

Effects of Eslicarbazepine Acetate (Esl, Bia 2-093) on Cognitive Function in Children With Partial Onset Seizures

NCT01527513 ·Status: COMPLETED ·Phase: PHASE2

The Effect of BIA 2-093 on the Steady-state Pharmacodynamic and Pharmacokinetic Profiles of Warfarin

NCT02287415 ·Status: COMPLETED ·Phase: PHASE1

Pharmacokinetics, Efficacy and Tolerability of BIA 2-093

NCT02170064 ·Status: COMPLETED ·Phase: PHASE2

A Placebo-controlled Study to Investigate Safety and Efficacy of BIA 2-093

NCT02170077 ·Status: COMPLETED ·Phase: PHASE2

Open-label Drug Interaction Study Between Eslicarbazepine Acetate and Lamotrigine.

NCT02283801 ·Status: COMPLETED ·Phase: PHASE1

Impact of Eslicarbazepine Acetate on Lipid Metabolism and Cardiovascular Risk Factors

NCT02573272 ·Status: UNKNOWN

Study to Test the Efficacy and Safety of Padsevonil as Adjunctive Treatment of Focal-onset Seizures in Adults With Drug-resistant Epilepsy

NCT03373383 ·Status: COMPLETED ·Phase: PHASE2

A Study in Participants With Epilepsy, to Evaluate the Pharmacokinetics, Safety and Tolerability of Oxcarbazepine on Padsevonil

NCT03695094 ·Status: COMPLETED ·Phase: PHASE1

An Open Label, Randomised, Repeat Dose Study to Assess the Pharmacokinetic Performance of Five Ezogabine/Retigabine Modified Release (MR) Formulations at Steady State Compared to the Immediate Release (IR) Formulation.

NCT01332513 ·Status: COMPLETED ·Phase: PHASE1